Mark Pruzanski, Versanis Bio CEO
July 20, 2022 07:00 AM EDTUpdated 07:42 AM
Startups
Bioregnum

Ex­clu­sive: Mark Pruzan­s­ki is once again reach­ing for the brass ring in biotech

Mark Pruzan­s­ki spent more than 18 years grow­ing In­ter­cept from a start­up to a com­mer­cial play­er look­ing for a land­mark ap­proval treat­ing NASH. But …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times